Introducing Validus Capital, a member of the Vertex Growth and Vertex SEA and India family.
A well-established major financial centre, Singapore is now a global nexus between the East and West, and is the preferred destination for many major corporations worldwide to set up their regional headquarters in Southeast Asia. But did you know that 99% of companies in Singapore are actually small and medium enterprises (SMEs)?
Validus Capital has joined the Singapore banks in offering government-backed loans under Enterprise Singapore's Enterprise Financing Scheme. The Singapore-based fintech this week secured official approval to offer small and medium-sized enterprises (SMEs) financing that has up to 90 per cent of the risk taken up by the government.
How meat and seafood brand Licious made the most of the pandemic tailwinds and now has revenue of Rs1,000 crore in its sights by March 2021. Can it get there?
The incredible growth during the pandemic didn’t come on its own. Much went behind the scenes, especially in cracking the supply chain, which had three critical components. First was getting hold of raw meat. The initial days of lockdown not only shut down everything, but also ensured confusion regarding movement of commercial vehicles. Poultry owners, hit hard by shutting down of hotels, restaurants and local markets, were in a fix as demand suddenly vanished. The second problem was taking care of factories, which not only had to be run but, as Sadana puts it, “had to be run safely, without letting the virus in”. Lastly, Licious had to ensure that the delivery channel—it has its own set of riders and doesn’t depend on online food aggregators like Swiggy and Zomato—were safe and had not contracted the virus. The big question, he lets on, was never about demand. “It was about supply.”
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4.
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the first patient has been dosed in the Phase IIa expansion portion of the Phase I/IIa trial sponsored by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research. The trial is evaluating BT1718 in patients with MT1-MMP-positive squamous non-small cell lung cancer (NSCLC) and a basket of other MT1-MMP-positive solid tumors.
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Dominic Smethurst, MA, MBChB, MRCP, MFPM as Chief Medical Officer. Dr. Smethurst brings to Bicycle extensive expertise in developing bispecific immuno-oncology agents, as well as toxin conjugate therapeutics for cancer and other serious diseases.
“Given his in-depth knowledge of conventional and disruptive therapeutic modalities, we believe Dominic is uniquely qualified to guide development of Bicycles as potential solutions to many of the limitations faced by small molecule and antibody-based medicines”